Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.52 |
| ▸ | PKM | P14618 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922873 | 0.80 | TDP1 (0.46) | NAMPTSMN1; SMN2ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL3909223 | 0.80 | TDP1 (0.45) | NAMPTSMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL23416155 | 0.76 | SLC40A1 (0.55) | KMT2AMEN1SLC40A1 | |
| SCHEMBL3915801 | 0.75 | SLC40A1 (0.45) | SMN1; SMN2ALDH1A1MAPTKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL3913472 | 0.74 | SLC40A1 (0.44) | SMN1; SMN2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL3908444 | 0.73 | HTR6 (0.46) | SLC40A1TSHR | |
| SCHEMBL3910472 | 0.72 | HTR2A (0.44) | SLC40A1 | |
| SCHEMBL1034598 | 0.71 | VNN1 (0.50) | NAMPTALDH1A1MAPTKMT2AIDO1 | |
| Hydrochloric Acid SCHEMBL3911171 | 0.71 | HTR2A (0.44) | SLC40A1 | |
| SCHEMBL3918840 | 0.71 | ALDH1A1 (0.48) | ALDH1A1MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928833-B1 | NOVEL QUINOLINE COMPOUNDS CAPABLE OF BINDING AT THE CB2 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | claimed |
| US-20080249092-A1 | Novel Quinoline Compounds Capable Of Binding At The Cb2 Receptor | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | US | claimed |
| EP-1928833-B1 | NOVEL QUINOLINE COMPOUNDS CAPABLE OF BINDING AT THE CB2 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20080249092-A1 | Novel Quinoline Compounds Capable Of Binding At The Cb2 Receptor | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| US-20080249092-A1 | Novel Quinoline Compounds Capable Of Binding At The Cb2 Receptor | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| US-20080249092-A1 | Novel Quinoline Compounds Capable Of Binding At The Cb2 Receptor | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007039220-A1 | NOVEL QUINOLINE COMPOUNDS CAPABLE OF BINDING AT THE CB2 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249092-A1 | Novel Quinoline Compounds Capable Of Binding At The Cb2 Receptor | CNR2, CNR1, GPR52 | NAMPT 1987/4885PKM 4316/4885SMN1; SMN2 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.